TeloCure
Gene Therapy for Hoyeraal-hreidarsson Syndrome
Health Tech & Life Sciences
Non Active, Oct 2019 ceased to operate
Company Overview
Snapshot
Founded in July 2018 by Noam Diamant, TeloCure operated with 1–10 employees. The company ceased operations in October 2019.
Business overview
TeloCure was focused on developing a gene therapy for Hoyeraal-Hreidarsson syndrome, an ultra-rare disease characterized by excessively short telomeres, which is a severe form of dyskeratosis congenita. The company operated within the Health Tech & Life Sciences sector, specifically targeting the Pharmaceuticals industry with its B2B business model.
Log in to access full profile ›Company Intelligence Q&A
- What was TeloCure's primary focus?
- TeloCure aimed to develop a gene therapy for Hoyeraal-Hreidarsson syndrome, an ultra-rare disease characterized by excessively short telomeres.
- When was TeloCure founded?
- TeloCure was founded in July 2018.
- What was the operational status of TeloCure?
- TeloCure ceased to operate in October 2019.
- Who was a key founder of TeloCure?
- Noam Diamant was a co-founder and CEO of TeloCure.
- In which sector did TeloCure operate?
- TeloCure operated within the Health Tech & Life Sciences sector, focusing on Pharma & Medical Biotechnology.